Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on January 26, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, CEO, President, Chairman, Director, and 10% Owner of IRADIMED CORP, reported transactions.
• On January 26, 2026, Susi sold a total of 5,000 shares of IRADIMED common stock.
• The sales were executed at weighted average prices of $100.54 for 4,339 shares and $101.38 for 661 shares.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
• The shares sold were held indirectly by the Phillip Susi 2008 Dynasty Trust.
• Following these transactions, Susi's indirect beneficial ownership includes 2,262,500 shares via the Phillip Susi 2008 Dynasty Trust, 162,950 shares via the Roger E. Susi Revocable Trust, and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust (with beneficial ownership disclaimed except for pecuniary interest).

Sentiment

Score: 4

Explanation: The CEO, President, and Chairman sold a significant number of shares, which can be perceived negatively by investors, although the sale was pre-arranged under a 10b5-1 plan, mitigating some of the negative sentiment.

Negatives

• Roger E. Susi, the CEO, President, and Chairman, sold 5,000 shares of common stock. While executed under a 10b5-1 plan, insider selling by top executives can sometimes be perceived negatively by the market.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Roger E. Susi, CEO, President, and Chairman, sold shares held indirectly by the Phillip Susi 2008 Dynasty Trust.
• Roger E. Susi also indirectly beneficially owns shares through the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust.

Stakeholder Impact

• Shareholders may interpret the insider sale as a potential signal, though the pre-arranged 10b5-1 plan suggests the decision was not based on recent material non-public information.

Key Dates

Recommendation

The filing reports an insider sale by the CEO, President, and Chairman, Roger E. Susi, under a pre-arranged 10b5-1 plan. While insider selling can sometimes signal a lack of confidence, the existence of a 10b5-1 plan suggests the decision was made in advance and not based on recent material non-public information. Without additional context on the company's performance or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future developments.

Keywords

IRADIMED, IRMD, Form 4, Insider Trading, Stock Sale, CEO, Roger E. Susi, 10b5-1 plan, common stock